The fusion between the ETS related gene (ERG), and the pro moter of the highlyexpressed transmembrane protease serine 2 (TMPRSS2) gene, is the most common recurrent genetic rear rangement in prostate adenocarcinoma.
The fusion between the ETS related gene (ERG), and the pro moter of the highlyexpressed transmembrane protease serine 2 (TMPRSS2) gene, is the most common recurrent genetic rear rangement in prostate adenocarcinoma. 1 It occurs in 15.372% 2, 3 of prostate cancers in the western population, but only in about 20.9 to 28% in Korean and Japanese populations. 46 Studies on the relationship between the TMPRSS2-ERG fusion and clini cal outcome in prostate adenocarcinoma yielded conflicting re sults. For instance, while Attard et al. 7 reported that the TM-PRSS2-ERG fusion is associated with poor overall survival, Sar amäki et al. 8 identified longer progressionfree survival. Fluorescence in situ hybridization (FISH) and quantitative polymerase chain reaction (QPCR) have been used to detect the fusion of ERG-TMPRSS2. 9 Recently, Park et al. 10 described a substantive detection method using the ERGspecific antibody EPR3864 in paraffinembedded tissue. Another group also re ported excellent correlation of ERG rearrangement using FISH. 11 Moreover, using semiquantitative methods in both prostate needle biopsy and radical prostatectomy specimens, 12 the inten sity of immunohistochemical staining has been associated with high ERG transcript levels. Falzarano et al. 13 reported that the overall specificity and sensitivity of ERG immunohistochemical staining were 99% and 96%, respectively. Immunohistochem istry (IHC) is a routine laboratory procedure and a relatively simple, lowcost method compared to other molecular tech niques such as FISH and QPCR. Therefore, given its costeffi ciency, immunohistochemical staining is a novel candidate ap proach for detecting ERG expression.
In this study, we analyzed ERG protein expression in large series of radical prostatectomy specimens using immunohisto chemical staining. We also investigated the relationship between IHC results and clinical and pathological parameters.
MATERIALS AND METHODS

Patient information
We collected paraffinembedded prostate tissue samples from a total of 303 patients who underwent radical prostatectomy between 1999 and 2006. Radical prostatectomy specimens were routinely cut in 4 mmthick transverse slices with perpen dicular sections from the apex to the base (bladder neck) and totally embedded in paraffin. The Gleason score, tumor vol ume, extraprostatic invasion, surgical margin status, seminal vesicle invasion, a pT and a pN stage were evaluated using pa thologic records and slide review. Age and preoperative, initial plasma levels of proteinspecific antigen (PSA) were collected from patient medical records. The Gleason pattern was assessed in accordance with the criteria outlined at the 2005 Interna tional Society of Urological Pathology (ISUP) Consensus Con ference.
14 A pathologic stage was assessed in accordance with the 7th Edition Cancer Staging Guidelines established by the Amer ican Joint Committee on Cancer in 2010.
Tissue microarray (TMA) construction
To construct the TMA, one representative core tumor tissue section (2 mm in diameter) was taken from an individual paraf fin block and arranged in a new TMA block using a trephine apparatus (SuperBioChips Laboratories, Seoul, Korea). 15 
Immunohistochemistry (IHC)
Sections mounted on superfrost slides were deparaffinized. IHC was conducted using Ventana Benchmark XT automated staining system (Ventana Medical Systems, Tucson, AZ, USA) and reagents, and an antiERG rabbit monoclonal antibody (RTU, clone EPR3864, Ventana Medical Systems). 10 Heatin duced epitope retrieval was performed for antiERG antibody. Primary antibody was incubated for 16 minutes at room tem perature. For IHC using the antiERG rabbit monoclonal anti body (rabbit ERGMAb), a secondary antibody (Ultraview anti Rabbit HRP, Ventana Medical Systems) was applied for 16 min utes at room temperature. Secondary antibody detection was performed using the Ultraview DAB detection kit (Ventana Medical Systems). Slides were counterstained with Hematoxy lin II for 4 minutes followed by the addition of Bluing Reagent (Ventana Medical Systems) for 4 minutes at 37.1˚C. The nuclei of endothelial cells were used as intrinsic positive control for ERG protein expression, as previously described. 10 To interpret ERG immunohistochemical staining, the intensity of ERG ex pression was scored as negative (0, no staining), weak (1+, only visible at high magnification), moderate (2+, visible at low mag nification) or strong (3+, striking at low magnification) (Fig. 1 ). Repeated immunohistochemical staining was performed using full section of a matched radical prostatectomy specimen in cas es where equivocal results were found in immunohistochemical staining using TMA.
Statistics
The chisquare test was used to compare the results of ERG immunostaining with clinicopathologic variables and the histo logic pattern. All reported pvalues were twosided, and signifi cance was set at p<0.05. All statistical analyses were conducted using SPSS ver. 19.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Clinicopathological factors
The mean age of prostatectomy patients was 65.7 years (me dian, 66 years; standard deviation [ SD ] , 6.4 years; range, 44 to 85 years). The mean initial PSA level was 11.0 ng/mL (median, 8.7 ng/mL; SD, 11.2 ng/mL; range, 1.7 to 98 ng/mL). The mean percentage of the tumor volume of the prostatectomy specimens was 18.6% (median, 10%; SD, 18.3%; range, 1 to 95%).
Correlation between ERG immunoreactivity and clinicopathological factors
Of the 303 cases, only 74 (24.4%) showed positive ERG im munohistochemical staining. Among them, 31.1% (26/74) were scored as 1+, 51.3% (38/74) as 2+, and 17.6% (13/74) as 3+. To perform subgroup analysis, the primary Gleason pattern was categorized into the group with grade 3 and the group with grade 4 or 5. The Gleason score was also categorized as below 7 and above 8. The pathologic staging was simply classified using pT2 (including pT2a, pT2b, and pT2c) and pT3 (including pT3a, pT3b, and pT3c).
The correlation between clinicopathological factors and ERG immunostaining is summarized in Table 1 . As shown in the Table, ERG expression was more frequently detected in the sub group with a lower primary Gleason grade than in the subgroup with a higher grade (p=0.004). Additionally, the frequency of ERG expression was significantly higher in the subgroup with the lower Gleason score (≤7) than in the subgroup with the higher score (p=0.011). No other clinicopathological factors correlated with ERG expression.
To evaluate the relationship between ERG protein expression detected by immunohistochemical staining and the histologic pattern of prostate adenocarcinoma subgroups were defined us ing the histologic patterns described in the 2005 ISUP Modi fied Gleason System (see Materials and Methods). Table 2 shows that ERG staining differed depending on the histologic pat tern. There was a significantly higher incidence of ERGposi tive staining in tumors with discrete glandular units (Gleason pattern 3; 69/225 cases, 27.1%) than in tumors without them (5/48 cases, 10.4%) (p=0.016). Although statistical signifi cance was not achieved due to the small sample size, the cases with large cribriform glands showed lower incidence of ERG positive staining (3/29 cases, 10.3%) than those without them (71/274 cases, 25.9%) ( Table 2 , Fig. 2 ). Moreover, 25 (33.8%) of the 74 ERG positive cases showed heterogeneous staining.
DISCUSSION
Tomlins et al. 1 first reported the recurrent genetic fusion of TMPRSS2 and ERG. ERG, a member of the ETS family of transcription factors, has been associated with normal develop mental processes, such as mesoderm formation, among others. 16 In contrast to mesenchymal tumors, the recurrent genetic fu sion that occurs during tumorigenesis is very rare in carcino mas. Furthermore, the TMPRSS2-ERG fusion may serve to ex plain the mechanism underlying oncogenic protein overexpres sion, although this case is not yet fully investigated. 17 Since the discovery of the TMPRSS2-ERG fusion, several groups have examined its clinical implications for the prognosis of prostate adenocarcinoma. However, because of the variability of study cohorts, clinical endpoints and the methods for gene fusion detection, the relationship between gene fusion and clin ical outcome has been variably described. Barwick et al. 18 re ported that the TMPRSS2-ERG fusion is associated with the prognosis of biochemical recurrence in multiple cohorts. On the other hand, Hermans et al. 19 concluded that a favorable prog nosis is significantly related to the TMPRSS2-ERG gene fusion. Several articles demonstrated that TMPRSS2-ERG gene fusion expression is an independent predictor of poor outcome in pros tate cancer patients. 20, 21 However, other studies have indicated that the ERG gene fusion has no significant clinical implications or prognostic value. 22, 23 In our study, the ERG positive rate was 24.4%, which is rela tively lower than those reported in western populationbased studies. Nevertheless, it has been observed that the frequency of the TMPRSS2-ERG gene fusion ranges widely from 15.3% to over 70% depending on the detection method and the study groups. 2, 3 In a study involving the Japanese population, a rela tively lower rate of ERG positivity has been reported (20.1% and 28%). 5, 6 Thus, in view of the present as well as the previous findings, it can be suggested that East Asian prostate cancer pa tients have a lower ERGpositive rate.
The associations between TMPRSS2-ERG gene fusion status and clinicopathologic parameters have varied between studies. While Attard et al. 7 found higher ERG gene fusion rate in tu mor cells with a higher Gleason grade, some groups reported no significant association between the Gleason pattern and ERG gene status. 24, 25 More recent studies, however, have shown that a lower Gleason grade is associated with a higher ERG gene fu sion rate. 26, 27 Notably, our results coincide with the findings of these recent studies.
Several previous reports also showed that a higher PSA level and a higher pT stage were positively associated with ERG fu sion rate. 3, 23 However, more recent studies identified lack of significant association between a T stage and a PSA level. 28, 29 We conclude that only primary Gleason patterns and Gleason scores are associated with a ERGpositive rate. Previous studies have also reported varied relationship between ERG gene fusion status and the histologic tumor pattern. Mosquera et al. 24 found that the ERG gene fusion is more frequently observed in higher grade features of prostate cancer. However, another study noted that the ERGpositive rate is higher in Gleason pattern 3 tu mors than in Gleason pattern 4 and 5 tumors. 28, 29 Our ERG immunohistochemical results showed a higher ERGpositive rate in tumors with Gleason pattern 3 which is represented by discrete glandular units. Moreover, although not statistically significant (p=0.071), a lower ERGpositive rate was observed in Gleason pattern 4 tumors containing large cribriform glands than in tumors without them. Furthermore, a number of stud ies have reported that heterogeneous ERG immunostaining was observed in the same tumor. 12, 28 In this study, we also observed heterogeneous ERG staining in 25 cases.
We previously reported the relationship between ERG gene rearrangement status and FISH analysis in the same cohort. 4 As such, we can compare the present immunohistochemical stain ing results to those of the FISH. Compared with the results on FISH, the sensitivity of ERG immunohistochemical staining is 89.8%, and the specificity is 96.4%.
In summary, using ERG immunohistochemical staining on TMA, we found the ERGpositive rate in Korean prostate can cer cases to be 24.4%. It is significantly higher in tumors with a lower Gleason grade represented by discrete glandular units, and in cases displaying a lower primary Gleason grade and a lower Gleason score. Nevertheless, this rate is relatively lower than those observed in studies involving western populations.
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